Mylan Receives Carbidopa and Levodopa ER Approval.Business Editors and Medical/Health Writers PITTSBURGH--(BUSINESS WIRE)--April 26, 2000 Mylan Laboratories Inc. (NYSE NYSE See: New York Stock Exchange :MYL MYL Mind Your Language MYL Made You Laugh MYL Miss You Lots MYL Meet You Later MYL Miss You Loads ) announced today that it has received approval from the Food and Drug Administration to manufacture and market Carbidopa and Levodopa levodopa: see l-dopa. levodopa or L-dopa Organic compound (L-3,4-dihydroxyphenylalanine) from which the body makes dopamine, a neurotransmitter deficient in persons with parkinsonism. Extended-Release Tablets in 25 mg/100 mg strength. Mylan had received final approval on the 50 mg/200 mg strength of Carbidopa and Levodopa Extended-Release Tablets in October and is the first company to market a generic version of this product. Carbidopa and Levodopa Extended-Release Tablets is the generic version of Sinemet(R) CR Tablets, a product of Du Pont Du Pont (d  pŏnt), family notable in U.S. industrial history. The Du Pont family's importance began when Eleuthère Irénée Du Pont established a gunpowder mill on the Pharmaceuticals Co. The product is indicated for the treatment of the symptoms of idiopathic Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. , postencephalitic parkinsonism and symptomatic parkinsonism. The product is being manufactured at Mylan's Morgantown, West Virginia facility and is being shipped immediately. For information regarding Mylan Laboratories Inc., we invite you to visit our corporate web site at www.mylan.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion